Search results for "3003"

showing 10 items of 115 documents

Effects of Diets Supplemented with Medicinal Mushroom Myceliated Grains on Some Production, Health, and Oxidation Traits of Dairy Ewes

2019

The beneficial properties of mushrooms’ bioactive compounds indicate their potential for use as performance-enhancing natural additives for livestock animals. A study was undertaken to evaluate the effects of diets supplemented with mushroom myceliated grains (MMGs) fed to dairy ewes on intestinal parasite load, milk production, milk fatty acid (FA) composition, and cheese oxidative stability. During an 8-week experimental period, 21 lactating Valle del Belice ewes were divided into 3 groups named MMG20, MMG10, and MMG0. Ewes in each group were fed hay ad libitum and 1.3 kg/day/head of 1 of 3 concentrates with MMGs at 20% (MMG20), 10% (MMG10), or 0% (MMG0). The ewes fed MMG20 had comparable…

Fungus myceliated grainMedicinal mushroomBiologyApplied Microbiology and BiotechnologyCheese oxidative stabilityEwechemistry.chemical_compoundAnimal scienceLipid oxidationCheeseCaseinLactationDrug DiscoverymedicineAnimalsLactationDry matterPharmacologySheepMyceliumDrug Discovery3003 Pharmaceutical ScienceFatty acidIntestinal parasite controlAnimal FeedEicosapentaenoic acidDietMilkmedicine.anatomical_structurechemistryHayAnimal Nutritional Physiological PhenomenaFemaleComposition (visual arts)TroloxAgaricalesEdible GrainInternational Journal of Medicinal Mushrooms
researchProduct

Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE--5-a population-based study

2013

Background: Cancer survival is a key measure of the effectiveness of health-care systems. EUROCARE-the largest cooperative study of population-based cancer survival in Europe-has shown persistent differences between countries for cancer survival, although in general, cancer survival is improving. Major changes in cancer diagnosis, treatment, and rehabilitation occurred in the early 2000s. EUROCARE-5 assesses their effect on cancer survival in 29 European countries. Methods: In this retrospective observational study, we analysed data from 107 cancer registries for more than 10 million patients with cancer diagnosed up to 2007 and followed up to 2008. Uniform quality control procedures were a…

GerontologyAdultMaleTime FactorsAdolescentColorectal cancerPopulationSettore MED/42 - Igiene Generale E ApplicataIR-88481NOProstate cancerBreast cancerMETIS-300341NeoplasmsmedicineHumansLung cancereducationAdolescent; Adult; Age Factors; Aged; Europe; Female; Humans; Male; Middle Aged; Neoplasms; Retrospective Studies; Time Factorsddc:613AgedRetrospective Studieseducation.field_of_studyRelative survivalbusiness.industryOncology cancer survival eurocareAge FactorsCancerRetrospective cohort studycancer survival ; age ; country ; Europe ; Eurocare 5Middle Agedmedicine.diseaseCancer survivalEuropeOncologyFemaleNeoplasms/mortalitybusinessDemography
researchProduct

Deciphering the Nonsense Readthrough Mechanism of Action of Ataluren: An in Silico Compared Study

2019

Ataluren was reported to suppress nonsense mutations by promoting the readthrough of premature stop codons, although its mechanism of action (MOA) is still debated. The likely interaction of Ataluren with CFTR-mRNA has been previously studied by molecular dynamics. In this work we extended the modeling of Ataluren's MOA by complementary computational approaches such as induced fit docking (IFD), quantum polarized ligand docking (QPLD), MM-GBSA free-energy calculations, and computational mutagenesis. In addition to CFTR-mRNA, this study considered other model targets implicated in the translation process, such as eukaryotic rRNA 18S, prokaryotic rRNA 16S, and eukaryotic Release Factor 1 (eRF…

In silicoNonsense mutationComputational biology01 natural sciencesRibosomeBiochemistrychemistry.chemical_compoundDrug DiscoveryQPLDcomputational mutagenesiMM-GBSA010405 organic chemistryChemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistrypremature termination codonSettore CHIM/06 - Chimica OrganicaSettore CHIM/08 - Chimica FarmaceuticaStop codon0104 chemical sciencesAtalurenInduced fit docking010404 medicinal & biomolecular chemistrySettore BIO/18 - GeneticaDocking (molecular)ProofreadingRelease factoroxadiazole
researchProduct

Novel 4-(3-phenylpropionamido), 4-(2-phenoxyacetamido) and 4-(cinnamamido) substituted benzamides bearing the pyrazole or indazole nucleus: synthesis…

2019

Based on some common structural features of known compounds interfering with p53 pathways and our previously synthesized benzamides, we synthesized new ethyl 5-(4-substituted benzamido)-1-phenyl-1H-pyrazole-4-carboxylates 26a-c, ethyl 5-(4-substituted benzamido)-1-(pyridin-2-yl)-1H-pyrazole-4-carboxylates 27a-c and N-(1H-indazol-6-yl)-4-substituted benzamides 31a,b bearing in the 4 position of the benzamido moiety the 2-phenylpropanamido or 2-phenoxyacetamido or cinnamamido groups. A preliminary test to evaluate the antiproliferative activity against human lung carcinoma H292 cells highlighted how compound 26c showed the best activity. This last was therefore selected for further studies wi…

IndazolesStereochemistryAntineoplastic AgentsApoptosisTRAIL-receptorPyrazole01 natural sciencesBiochemistrychemistry.chemical_compoundDownregulation and upregulationCell Line Tumor2-(3-phenylpropanamido)benzamideDrug DiscoverymedicineHumansMoietyMolecular BiologyCell ProliferationBiological evaluationP53Indazole010405 organic chemistryDrug Discovery3003 Pharmaceutical Science2-cinnamamidobenzamideOrganic ChemistryApoptosi2-(2-phenoxyacetamido)benzamide0104 chemical sciences010404 medicinal & biomolecular chemistrymedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Mechanism of actionchemistryApoptosisBenzamidesPyrazolesDrug Screening Assays Antitumormedicine.symptomNucleusBioorganic Chemistry
researchProduct

3-[4-(1H-indol-3-yl)-1,3-thiazol-2-yl]-1H-pyrrolo[2,3-b]pyridines, nortopsentin Analogues with antiproliferative activity

2015

A new series of nortopsentin analogues, in which the imidazole ring of the natural product was replaced by thiazole and the indole unit bound to position 2 of the thiazole ring was substituted by a 7-azaindole moiety, was efficiently synthesized. Two of the new nortopsentin analogues showed good antiproliferative effect against the totality of the NCI full panel of human tumor cell lines (~60) having GI50 values ranging from low micromolar to nanomolar level. The mechanism of the antiproliferative effect of these derivatives, investigated on human hepatoma HepG2 cells, was pro-apoptotic, being associated with externalization of plasma membrane phosphatidylserine and mitochondrial dysfunctio…

IndolesHalogenationPyridines3-b]pyridinesPharmaceutical ScienceApoptosisAntiproliferative activity3-[4-(1<i>H</i>-indol-3-yl)-13-thiazol-2-yl]-1<i>H</i>-pyrrolo[23-<i>b</i>]pyridineschemistry.chemical_compoundNeoplasmsDrug DiscoveryImidazoleMoietyindolyl alkaloidsPharmacology Toxicology and Pharmaceutics (miscellaneous)lcsh:QH301-705.5Membrane Potential MitochondrialMolecular Structure3-[4-(1H-indol-3-yl)-1; 3-thiazol-2-yl]-1H-pyrrolo[2; 3-b]pyridines; Antiproliferative activity; Indolyl alkaloids; Marine alkaloids; Nortopsentin analogues; Drug Discovery3003 Pharmaceutical ScienceImidazolesPhosphatidylserineMitochondrianortopsentin analoguesIndolyl alkaloidmarine alkaloidsG2 PhaseStereochemistryNortopsentin analogueAntineoplastic AgentsMethylationResting Phase Cell CycleArticleAlkaloids3-[4-(1H-indol-3-yl)-1Cell Line TumorHumansPyrroles3-[4-(1H-indol-3-yl)-13-thiazol-2-yl]-1H-pyrrolo[23-b]pyridines3-thiazol-2-yl]-1H-pyrrolo[2ThiazoleCell ProliferationIndole testNatural productCell growthDrug Discovery3003 Pharmaceutical ScienceSettore CHIM/08 - Chimica FarmaceuticaThiazoleschemistrylcsh:Biology (General)Cell cultureDrug DesignMarine alkaloid3-[4-(1H-indol-3-yl)-13-thiazol-2-yl]-1H-pyrrolo[23-b]pyridine
researchProduct

Synthesis of isoindolo[1,4]benzoxazinone and isoindolo[1,5]benzoxazepine: two new ring systems of pharmaceutical interest

2015

Abstract Two new ring systems, isoindolo[1,4]benzoxazinone and isoindolo[1,5]benzoxazepine, were conveniently synthesized through cyclization of suitably substituted isoindole derivatives. Some of the new compounds exhibited antiproliferative activity against a wide range of human tumor cell lines with GI 50 mean values at low micromolar level (3.72–5.13 μM).

Isoindolo[15]benzoxazepineChemistryStereochemistryDrug Discovery3003 Pharmaceutical ScienceOrganic Chemistry5]benzoxazepine4]benzoxazinoneAntiproliferative activityRing (chemistry)Settore CHIM/08 - Chimica FarmaceuticaBiochemistryHuman tumorchemistry.chemical_compoundIsoindolo[14]benzoxazinoneDrug DiscoveryIsoindolo[1Antiproliferative activity; Isoindole; Isoindolo[1; 4]benzoxazinone; Isoindolo[1; 5]benzoxazepine; Biochemistry; Organic Chemistry; Drug Discovery3003 Pharmaceutical ScienceIsoindoleIsoindole
researchProduct

The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target?

2014

Abstract: The advent of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represented the most important innovation in NSCLC treatment over the last years. However, despite a great initial activity, secondary mutations in the same target, or different alterations in other molecular pathways, inevitably occur, leading to the emergence of acquired resistance, in median within the first year of treatment. In this scenario, the mesenchymal-epidermal transition (cMET) tyrosine kinase receptor and its natural ligand, the hepatocyte growth factor (HGF), seem to play an important role. Indeed either the overexpression or the amplification of cMET, as well as the overexpr…

Lung NeoplasmscMETcMET; cMET-Inhibitors; EGFR-TKIs resistance; HGF; NSCLC; Targeted therapies; Molecular Medicine; Pharmacology; Drug Discovery3003 Pharmaceutical Science; Clinical BiochemistryClinical BiochemistryAntineoplastic AgentsBiologyPharmacologyNSCLCReceptor tyrosine kinaseTargeted therapiesCarcinoma Non-Small-Cell LungDrug DiscoverymedicineHumansEpidermal growth factor receptorHGFLung cancerProtein Kinase InhibitorsEGFR inhibitorsEGFR-TKIs resistancePharmacologyClinical Trials as TopicPharmacology. TherapyDrug Discovery3003 Pharmaceutical ScienceAntibodies MonoclonalProto-Oncogene Proteins c-metmedicine.diseaseMolecular medicinerespiratory tract diseasesErbB ReceptorsDrug Resistance NeoplasmProto-Oncogene Proteins c-metbiology.proteinCancer researchMolecular MedicineDrug Therapy CombinationHepatocyte growth factorcMET-InhibitorTargeted therapiecMET-InhibitorsTyrosine kinasemedicine.drug
researchProduct

Anti-cytokine therapy for prevention of atherosclerosis

2015

Abstract Background Currently a chronic inflammation is considered to be the one of the most important reasons of the atherosclerosis progression. A huge amount of researches over the past few decades are devoted to study the various mechanisms of inflammation in the development of atherosclerotic lesions. Purpose To review current capabilities of anti-inflammatory therapy for the prevention and treatment of atherosclerosis and its clinical manifestations. Methods Appropriate articles on inflammatory cytokines in atherosclerosis and anti-inflammatory prevention of atherosclerosis were searched in PubMed Database from their respective inceptions until October 2015. Sections “The role of infl…

Male0301 basic medicine3003Anti-Inflammatory AgentsPharmaceutical ScienceInflammation030204 cardiovascular system & hematologyBioinformaticsProinflammatory cytokineAnti-Cytokine TherapyDouble blind03 medical and health sciences0302 clinical medicineDouble-Blind MethodDrug DiscoverymedicineAnimalsHumansInterleukin 6InflammationPharmacologybiologyTraditional medicinebusiness.industryMedicine (all)Drug Discovery3003 Pharmaceutical ScienceAtherosclerosisComplementary and Alternative Medicine2708 DermatologyHerbal preparationClinical trial030104 developmental biologyComplementary and alternative medicineAtherosclerosis preventionDisease Progressionbiology.proteinCytokinesHerbal preparationsAtherosclerosis preventionMolecular MedicinePlant Preparationsmedicine.symptomAnti-cytokine therapybusiness
researchProduct

Smart copolymer coated SPIONs for colon cancer chemotherapy

2019

Human colon cancer is one of the higher aggressive solid tumors, whose high mortality, much like many other solid tumors, results from metastasis formation. To reduce this high mortality, more effective chemotherapy, allowing a specific tumor accumulation and an efficient early-stage medical imaging as well, are still needed. At this regard, stimuli-responsive nanocarriers for anticancer drug delivery are promising strategy in cancer therapy. For this purpose, a dual targeted redox-responsive drug delivery system, prepared by coating superparamagnetic nanoparticles (SPIONs) with the amphiphilic copolymer INU-LA-PEG-FA and loading doxorubicin (DOXO-SPIONs) was investigated as tool for solid …

Male3003Colorectal cancerPolymersmedicine.medical_treatmentPharmaceutical ScienceMice Nude02 engineering and technologyDual targeting030226 pharmacology & pharmacyPolyethylene Glycols03 medical and health scienceschemistry.chemical_compoundMice0302 clinical medicineDrug Delivery SystemsFolic AcidmedicineAnimalsHumansDoxorubicinReceptorMagnetite NanoparticlesRedox-responsiveChemotherapyAntibiotics Antineoplasticmedicine.diagnostic_testThioctic AcidInulinSPIONMagnetic resonance imaging021001 nanoscience & nanotechnologymedicine.diseaseMagnetic Resonance ImagingXenograft Model Antitumor AssaysUp-RegulationLipoic acidchemistryDoxorubicinSettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliveryColonic NeoplasmsCancer researchCancer chemotherapyNanocarriers0210 nano-technologyOxidation-Reductionmedicine.drugMRI
researchProduct

The Anticonvulsant FCE 26743 is a Selective and Short-acting MAO-B Inhibitor Devoid of Inducing Properties towards Cytochrome P450-dependent Testoste…

1994

Abstract The effects of the potent anticonvulsant FCE 26743 ((S)-2-(4-(3-fluorobenzyloxy)benzylamino)propionamide) on monoamine oxidase (MAO) activity were measured in-vitro and ex-vivo using rat tissue homogenates. In-vitro, FCE 26743 showed potent and selective inhibitory properties towards liver MAO-B, with IC50 values about 10−7  m for MAO-B and higher than 10−5  m for MAO-A. When determined ex-vivo in brain, the ED50 value for the inhibition of MAO-B was 1·1 mg kg−1 (p.o.) 1 h post-dosing, whereas MAO-A remained virtually unaffected after administration of 60 mg kg−1. Similar effects were seen in liver. Following oral administration of 5 mg kg−1 FCE 26743 to rats, brain MAO-B inhibitio…

MaleBenzylaminesMonoamine Oxidase InhibitorsMonoamine oxidaseMetabolite3003 Pharmaceutical Science10050 Institute of Pharmacology and ToxicologyPharmaceutical Science610 Medicine & healthMice Inbred StrainsIn Vitro TechniquesPharmacologyHydroxylationRats Sprague-DawleyHydroxylationMicechemistry.chemical_compoundCytochrome P-450 Enzyme SystemOral administrationmedicineAnimalsTestosteroneED50PharmacologyAlanineDose-Response Relationship DrugbiologyChemistryBrainCytochrome P450Rats3004 PharmacologyLiverMechanism of actionbiology.protein570 Life sciences; biologyAnticonvulsantsMonoamine oxidase Bmedicine.symptomJournal of Pharmacy and Pharmacology
researchProduct